Education
About Us
Working with TipRanks
Follow Us
Intuitive Surgical (GB:0R29)
LSE:0R29
0R29 Stock Chart & Stats
$503.22
$9.50(1.78%)
At close: 4:00 PM EST
$503.22
$9.50(1.78%)
Day’s Range― - ―
52-Week Range$406.50 - $603.32
Previous CloseN/A
Volume1.49K
Average Volume (3M)2.32K
Market Cap
$175.44B
Enterprise Value$176.69B
Total Cash (Recent Filing)$5.93B
Total Debt (Recent Filing)$302.80M
Price to Earnings (P/E)63.9
Beta1.03
Next Earnings
Apr 21, 2026EPS Estimate
2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.53
Shares Outstanding355,130,250
10 Day Avg. Volume2,029
30 Day Avg. Volume2,319
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue17.56
Enterprise Value/Gross Profit26.60
Enterprise Value/Ebitda48.77
Forecast
1Y Price Target
$647.56Price Target Upside28.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)10.04
Revenue Forecast (FY)$11.52B
Bulls Say, Bears Say
Bulls Say
Acquisition Of Tissue-assessment TechnologyAcquisition of a company developing integrated robotics and AI for biopsy tissue assessment can broaden the surgical robotics portfolio and enable applications across lung, liver, pancreas, breast and lymph node procedures, expanding the addressable market.
Advanced Dye-free Imaging PipelineDevelopment of dye-free hyperspectral tissue oxygenation imaging that provides quantitative oxygenation maps could reduce subjective interpretation, improve decision-making in surgery and complement existing imaging techniques to enhance outcomes.
New-generation Surgical Robot And Fleet ExpansionIntroduction of a new-generation surgical robot can trigger system upgrades, fleet expansion and deployment of refurbished units, enabling more hospitals to adopt minimally invasive and complex surgeries and supporting procedure volume growth.
Bears Say
Limits Of Biopsy Technology SubstitutionRobotic biopsy assessment technology does not replace trained pathologists, which may limit immediate substitution of laboratory workflows and slow realization of workflow efficiencies.
Pace Of Cardiac Procedure AdoptionComplexity of cardiac surgeries suggests robotic conversion will be gradual, limiting rapid market penetration and slowing revenue ramp in new cardiac indications such as coronary bypass and mitral valve procedures.
Trade-ins And Unit Placement PressureRising trade-in activity could reduce net system placements even if gross shipments appear healthy, creating downside risk for reported unit growth and complicating near-term sales momentum.
Intuitive Surgical News
0R29 FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest share price was $406.50 and its highest was $603.32 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $175.44B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Apr 21, 2026 which is in 54 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jan 22, 2026. The company reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.267 by $0.263.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Intuitive Surgical dividends here
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.13.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 355,130,250 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $2.53 in its last earnings report, beating expectations of $2.267. Following the earnings report the stock price went down -0.862%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in GB:0R29
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$647.56 (28.68% Upside)
$647.56 (28.68% Upside)
Blogger Sentiment
Bullish
GB:0R29 Sentiment 82%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.77%
12-Months-Change
Fundamentals
Return on Equity
16.67%
Trailing 12-Months
Asset Growth
9.52%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
0R29 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong top-line and procedure growth, meaningful increases in cash flow and profitability, rapid adoption of new platforms (da Vinci 5, SP, Ion), and continued product and clinical progress. Offsetting these positives are margin pressures from tariffs and product mix, elevated operating expenses (including a large foundation donation and hiring), competitive pricing/tender dynamics in China, placement softness in Japan, and lower Ion placements in Q4. On balance the company reported multiple high-growth metrics and solid cash generation while outlining manageable but notable near-term headwinds.View all GB:0R29 earnings summaries0R29 Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
0R29 Stock 12 Month Forecast
Average Price Target
$647.56
▲(28.68% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Hologic
―
Resmed
―
West Pharmaceutical Services
―
Options Prices
Currently, No data available
---